Preclinical News and Research

RSS

Nanoparticles Boost Delivery of Lung Cancer Drugs 30-Fold

Lung cancer remains one of the world’s deadliest cancers, yet despite decades of effort to develop new drugs, many fail because they don’t stay in the body long enough to be effective or because they damage healthy organs.

1 Jun 2026

MRM Health Rewarded a € 2.6 M VLAIO Research Grant to Accelerate the Development of Novel Therapeutics that Redefine the Treatment of Immune-Mediated Inflammatory Diseases

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that it has been awarded a research grant of € 2.6M from Flanders Innovation and Entrepreneurship (VLAIO), a government organization with the goal to stimulate economic development in Flanders, Belgium.

29 May 2026

Macrophage Placement Determines if Tumors Thrive or Regress

Cancer tumors are surrounded by immune cells, but not all of those cells help the body fight back. Some support anti-cancer immunity, while others can unexpectedly help tumors survive.

27 May 2026

Ovarian Cancer Fluid Helps Tumors Evade Cell Death

Ascites in ovarian cancer rewires tumor metabolism, protecting cells from ferroptosis and promoting metastasis, revealing potential therapeutic targets.

27 May 2026

Researchers Link Brain Extracellular Matrix Deterioration to Postmenopausal Memory Loss

A largely overlooked space between cells in women's brains may hold the key to understanding memory loss tied to estrogen decline after menopause, reports a new preclinical Northwestern Medicine study.

26 May 2026

Researchers Reverse Immune Cell Dysfunction by Degrading Key Gene Regulatory Proteins

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma.

20 May 2026

Study Reveals New Biological Pathway for TNF-Resistant Crohn’s Disease

Mayo Clinic researchers have identified an immune-regulating molecule that may help explain why some patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, do not respond to commonly used therapies.

14 May 2026

AI Designs New Antibiotics That Reduce MRSA Infections In Mice

SyntheMol-RL integrates reinforcement learning for antibiotic design, producing synthesizable candidates that show efficacy against MRSA in preclinical models.

5 May 2026

Metabolic Pathway Loss Makes Cancer Cells Vulnerable to PARP Drugs

Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.

5 May 2026

Intermediate PRRX1 Levels Drive Breast Cancer Metastasis Risk

The study identifies PRRX1 as a critical factor in breast cancer metastasis, highlighting its potential as a biomarker for predicting aggressive disease.

29 Apr 2026

Researchers Develop 3D Organoids that Reflect the Complexity of Brain Tumors

Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children's Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.

16 Apr 2026

New Experimental System Mimics Low-Grade Pediatric Glioma in 3D

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children.

10 Apr 2026

Semen-Derived Exosomes Eye Drops to Treat Retinoblastoma

Innovative eye drops using semen-derived exosomes target retinoblastoma, improving therapeutic delivery and preserving ocular function in preclinical models.

8 Apr 2026

New Mouse Model Reveals Viral Path to Liver Cancer

Liver cancer is one of the world's deadliest cancers, and most cases are linked to chronic viral hepatitis. Yet scientists have lacked an animal model that faithfully recapitulates how the disease unfolds in people, from initial infection with a virus to liver inflammation, scarring, and cancer.

7 Apr 2026

Tumors Disable Dendritic Cells by Decreasing Mitochondrial Fitness

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring their energy production can improve immunotherapy.

3 Apr 2026

Defining Tumor Microbiota for Improved Cancer Diagnosis and Treatment

Recent research shows that tumors in different organs host microbial communities capable of influencing cancer biology, immune responses, and the effectiveness of therapies, highlighting the need to standardize methods for studying intratumoral microbes.

3 Apr 2026

Regenerative Vascular Grafts Solve Key Shortage In Surgery

Engineered biotubes demonstrate strong mechanical performance and rapid tissue regeneration, offering a scalable solution to the vascular graft shortage.

2 Apr 2026

A Python-Inspired Molecule Suppresses Appetite After Eating

The study identifies pTOS as a key metabolite in appetite suppression, highlighting a gut–liver–brain pathway with implications for obesity therapy.

2 Apr 2026

Novel Immunotherapy Disrupts the Protective Tumor Microenvironment Ecosystem

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two main reasons: tumor cells often don't share one consistent surface target, and many solid tumors are protected by a dense network of scar tissue and immune-suppressive cells that blocks T cells.

31 Mar 2026

New Mechanism Links Mitochondria Dysfunction to T Cell Exhaustion

The immune system's killer T cells do a commendable job of detecting and destroying cancer cells. But the harsh environment at the heart of tumors often saps them of their vitality, pushing them into a state of permanent lassitude called "terminal exhaustion."

23 Mar 2026